Impact of thrombus aspiration conjugative with Anisodamine for the Prevention of No-reflow phenomenon following primary Percutaneous coronary intervention

Abstract

Objective:We sought to evaluate the combination therapy of thrombus aspiration plus anisodamine in prevention of No-reflowphenomenon during percutaneous coronary intervention.method:fromOctober 2009to June,143 consecutive patients with STEMI who received manualthrombus aspiration were involved in a Double Center prospectively analysis.The patients were treated with anisodamine (1000fig/kg)plus Tirofiban (pg/kg) (Group A,n = Tirofiban and pg/kg alone (group B,n = respectively.The drugswere selectively injected into the infarct-related artery (IRA),Through the occlusion to the distal segment via the Thrombus ASPI Theration catheter advanced MTO the IRA.Primary endpoints were postprocedural corrected thrombolysis in myocardial frame count (infarction).The proportion of complete c>70%)St-segment resolution (STR) myocardial blush Grade 2~3 (MBG) post PCI.Secondary endpoints included peak value of creatine kinase - MBTIMI flow grade;6-month outcome including left ventricular ejection fraction (LVEF),b16> as acardiac death target vascular revascularization,Re-infarction and their combination as major adverse cardiac events (MACE).result:Baseline characteristicswere not different between two groups.Compared to group B,Group A had①A lower corrected TIMI coronary flame count (_p ,②ahigher proportionof completest-Segment Resolution (_P 0.No differences were foundin Cardiac Death,tvr,r^infarction,mace,between The two groups during 6-month follow-upOnly a improvement trend in groupeight(P0.05).Nevertheless, LVEF at6 month is higher in groupEight(P(0.01).Conclusion: preventively intracoronary Administration of Anisodamine 1000 ug via thrombus aspiration catheter can improve myocardiAl reperfusion for acute STEMI with initial timi^2 treated with primary PCI.